研究发现GLP-1药物将糖尿病患者的手术后并发症减少多达56%。 Study finds GLP-1 drugs reduce post-surgery complications in diabetic patients by up to 56%.

Weill Cornell Medicine和哥伦比亚大学的一项研究表明,GLP-1受体激动剂药物,如tirzepatide 和 simaglutide,可以大大降低糖尿病患者的外科后并发症。 A study from Weill Cornell Medicine and Columbia University shows that GLP-1 receptor agonist drugs, like tirzepatide and semaglutide, can significantly lower post-surgery complications for diabetic patients. 研究覆盖了21 772名病人的74 425个外科手术,为期三年半,发现这些药物减少了12%的住院复诊,29%的伤口重开,56%的血肿。 The research, covering 74,425 surgeries in 21,772 patients over three and a half years, found these drugs reduced hospital readmissions by 12%, wound re-opening by 29%, and hematomas by 56%. 这可能会导致糖尿病患者外科治疗的改变。 This could lead to changes in surgical treatment for diabetes patients.